Equities

Mainz Biomed NV

Mainz Biomed NV

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.3929
  • Today's Change0.039 / 11.08%
  • Shares traded5.48k
  • 1 Year change-87.20%
  • Beta--
Data delayed at least 15 minutes, as of Sep 03 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.

  • Revenue in USD (TTM)895.48k
  • Net income in USD-26.30m
  • Incorporated2021
  • Employees65.00
  • Location
    Mainz Biomed NVSirius Gutenberg ParkRobert-Koch-Strasse 50MAINZ 55129GermanyDEU
  • Phone+49 61 315542860
  • Websitehttps://www.mainzbiomed.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Syra Health Corp7.07m-4.19m6.68m78.00--3.19--0.9447-0.6709-0.67091.190.31692.81--11.2790,635.38-166.37---287.17--23.56---59.23-----177.320.0518---1.83---38.72------
Ethema Health Corp5.27m943.69k6.96m65.004.09--6.831.320.00020.00020.0014-0.00220.6511--14.1781,064.167.10-37.68--------10.91-94.87---1.777.30--10.8765.34652.41--74.97--
Kindly MD Inc3.10m-2.44m6.96m23.00--1.59--2.25-0.4652-0.46520.57430.73760.98675.94471.36134,643.90-77.81---99.26--93.94---78.86--5.36-5.610.0517---0.488--36.34------
Inspire Veterinary Partners Inc17.13m-19.33m7.10m156.00------0.4147-134.72-134.724.54-0.6310.816521.61246.52109,778.20-89.79---190.96--19.47---109.98--0.1311-2.741.20--69.56---206.68------
Mangoceuticals Inc866.79k-9.13m8.07m----0.5686--9.31-0.4388-0.43880.0410.47470.093519.32-----98.48---107.62--58.19---1,052.90--0.3653-38.860.0134--8,082.22---361.07------
US NeuroSurgical Holdings Inc0.00-1.02m8.09m2.00--4.05-----0.0928-0.09280.000.14820.00----0.00-45.80-14.62-66.91-19.89-------36.77----0.00------38.97------
Caremax Inc784.55m-782.86m8.24m1.45k------0.0105-208.41-208.41208.34-38.730.9776--6.10541,069.60-97.55---160.21---3.31---99.78-----1.951.57--19.01---1,707.99------
NewGenIvf Group Ltd0.00-690.85k8.48m----0.1998-----0.1999-0.19990.004.190.00-------1.50---1.54--------------0.0944-------237.99------
Xcelerate Inc3.96m-296.19k8.50m1.00--6.11--2.15-0.0014-0.00140.01890.00321.516.133.90---11.334.24-49.19--71.7174.10-7.481.930.4797-0.82180.7237--6.6310.4317.00--174.06--
Mainz Biomed NV895.48k-26.30m8.60m65.00--2.56--9.60-1.67-1.670.05540.15350.05020.977911.3913,776.62-147.52---237.21--56.91---2,936.50--0.9057-32.910.6629--69.00--0.3472------
Ontrak Inc12.39m-36.52m9.36m102.00--0.6075--0.756-2.35-2.350.30570.32130.5173--12.53121,421.60-115.11-54.80-157.11-73.3766.8153.50-222.54-71.95---1.730.3021---12.20-3.4439.08--99.58--
Aesthetic Medical Intl Hldg Grp Ltd(ADR)102.05m-6.80m9.56m1.29k--2.444.750.0937-0.1509-0.15092.250.08191.2920.8277.3679,352.31-9.06-23.36-35.45-48.5845.3955.32-7.02-23.720.2031-5.500.9581--1.86-2.1650.91--3.70--
Univec Inc-100.00bn-100.00bn10.09m3.00---------------0.0113-----------50.96------17.47---198.310.0051-------74.07-64.8336.83------
Pacific Health Care Organization Inc6.02m873.35k10.26m30.0011.760.914711.271.710.06820.06820.46930.87630.5208--6.67200,501.307.567.298.107.8178.9782.7514.5213.28----0.00---2.00-3.7055.80-10.80-15.93--
Data as of Sep 03 2024. Currency figures normalised to Mainz Biomed NV's reporting currency: US Dollar USD

Institutional shareholders

0.47%Per cent of shares held by top holders
HolderShares% Held
Bank Vontobel AGas of 30 Jun 202425.00k0.11%
Geode Capital Management LLCas of 30 Jun 202415.19k0.07%
Northern Trust Global Investments Ltd.as of 30 Jun 202414.97k0.07%
Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 202414.97k0.07%
XTX Markets LLCas of 30 Jun 202411.36k0.05%
Greenwich Investment Management, Inc.as of 30 Jun 202410.86k0.05%
Wealth Quarterback LLCas of 30 Jun 202410.00k0.05%
Citigroup Global Markets, Inc. (Investment Management)as of 30 Jun 2024673.000.00%
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 2024200.000.00%
BofA Securities, Inc.as of 30 Jun 2024100.000.00%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.